Ninewells Cancer Campaign - Help Dennis beat the menace!

Welcome to the Ninewells Cancer Campaign website

Our sole aim is to beat cancer. We have made great strides in research over the past 20 years, and are delighted to announce that we have succeeded in raising the £1.5 million we needed for our recent Personalised Medicine campaign. With this money, we've been able to build and equip new laboratories, and research into personalised medicine is now taking place.

However, the fight goes on. New equipment and advances in screening are vital. To keep up the fight, we turn again to the people of Scotland, through the Ninewells Cancer Campaign, which has supported us so magnificently in the past. With your help, Dundee research may yet rid the world of the scourge of cancer.

Please help us all you can. Thank you.

DR Jacqui Wood MBE JP DL
Chairman of the NCC until her sad death, from cancer, in May 2011



November 2011: Please Note: The NCC has just embarked on a major fundraising campaign to raise £2 million to help complete the move to a new dedicated cancer research building at Ninewells Hospital and Medical School, which will bear Jacqui's name. Work is presently being undertaken to update this website.


Latest news item

Screening: A re-evaluation of KRAS mutational ‘hotspots’

May 12th, 2010

KRAS mutational status is known to be both a prognostic and predictive biomarker in patients with colorectal cancer. Specifically, mutations in ‘hotspot’ codons of the KRAS gene are associated with more aggressive disease in these individuals and with a poor response to EGFR inhibitors. However, recent work from Gillian Smith and colleagues might increase the clinical utility of this biomarker, as the authors have identified additional KRAS mutations that they recommend for inclusion in routine screening of KRAS mutational status in these patients. “We realized that there has been no systematic assessment of KRAS mutation burden outwith the hotspot codons, so we decided to screen the entire KRAS gene for mutations in a cohort of patients with colorectal cancer,” explains Smith.
Read the rest of this entry »